Little is known about the function and phenotype of leukemic stem cells (LSCs) in chronic myeloid leukemia (CML) or about specific markers that discriminate LSCs from normal hematopoietic stem cells (HSCs). CD26 has recently been described as a specific marker of CML LSCs. In the current study, we investigated this marker 
INTRODUCTION
The BCR-ABL1 oncogene is a driver of initiation and progression in chronic myeloid leukemia (CML) [1] . The tyrosine kinase inhibitors (TKIs) directed against the BCR-ABL1 oncoprotein have proven to be successful in the treatment of CML. Today, CML patients benefit from long-term responses induced by imatinib and other BCR-ABL1 TKIs [2, 3] . However, leukemic stem cells (LSCs) often survive TKI therapy and may be responsible for treatment failure and relapse [4, 5] . The LSC resistance to TKIs can result from acquired mechanisms, such as the selection of subclones with mutations in the BCR-ABL1 oncogene, or may involve intrinsic mechanisms, such as LSC dormancy [6] [7] [8] . Moreover, increasing evidence suggests an important role of the microenvironment in LSC resistance [3, 9] .
Current research in CML has focused on the identification and characterization of LSCs. This might enable eradication of LSCs and provide a curative therapy in CML. However, the identification of LSCs and their separation from normal hematopoietic stem cells (HSCs) in CML is challenging, since both populations reside in the same compartment phenotypically defined as www.impactjournals.com/oncotarget CD45 + 34 + 38
- [10] . Recently, several groups have reported on more or less specific LSC markers and LSC-related light scatter properties in CML [10] [11] [12] [13] [14] [15] [16] . One of such markers appears to be IL-1RAP, while another is CD26, which is also known as dipeptidylpeptidase IV (DPPIV). This functionally relevant cell surface antigen as well as IL-1RAP is specifically expressed on CML LSCs, but not on HSCs [10] . LSC-specific markers, such as IL-1RAP or CD26, may also represent suitable targets for anti-LSC therapy as well as potential prognostic markers [17] . More recent data suggest that the levels of CD26 on CML LSCs may vary from patient to patient [10, 17] [18, 19] . In this article, the CD45 + 34 + 38 -compartment is simply referred to as the "stem cells (SCs)". The investigated CD26 + and CD26 -SC populations were well identifiable, although they varied in size among patients and were sometimes very small or even missing in some sets of the patients (Figures 1-2) . Overall, three patterns of expression of CD26 on SCs were observed and the patients were categorized into 3 groups accordingly: Group 1 was characterized by a dominant CD26 + SC population, Group 2 by similar ratio of CD26 + and CD26 -SCs, and Group 3 by a dominant CD26
-SC compartment (Table 1 ). 
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-SCs. All of the CD26 + subfractions were proven to be BCR-ABL1+ irrespective of CD38 expression. In contrast, the CD26 -subfractions which corresponded to strictly CD38 -gated cells contained only BCR-ABL1 negative cells, and the positivity started to "occur" only in subfractions with CD38 dim expression, which supposedly contained the leukemic CD34 + progenitor cells (subfractions no. 3-5; Figure 4 ).
RT-PCR analysis confirms that CD26 staining can safely discriminate between LSCs and HSCs in all three groups of CML patients

CD26 -SCs show low forward scatter (FSC)
In order to verify alternative options for identifying and separating LSCs and HSCs, we performed additional visualization of the CD26 -SC population in FSC histograms ( Figure 5 ). The FSC low population perfectly matched the CD26 -SC population, which was nicely demonstrated in Group 2 and 3 patients. In Group 1 patients who virtually lacked CD26 -SCs, the FSC low population was also absent ( Figure 5 ).
Correlation of the percentage of CD26 + SCs with clinical parameters in CML patients
We further assessed whether the percentage of CD26 + SCs and the resulting group categorization correlated with clinical or prognostic parameters in our CML patients (Table 2) . A statistically significant difference was found between the mean white blood counts (WBC) at the time of diagnosis among the 3 groups (n = 31, p < 0.001; Kruskal-Wallis; ANOVA). In particular, as expected, patients with higher WBC were found to have higher levels (percentages) of CD26 + SCs within the total SC compartment. We also correlated response to imatinib with the percentage of CD26 + SCs in a homogeneous subgroup of first-line imatinib-treated patients (n = 15). In these patients, achievement of major molecular response (MMR) at month 12 (n = 15) was significantly different among the 3 groups, with the best response seen in Group 3 patients (p < 0.05; Fisher's exact test). However, no such relationship was found at month 18, when 12/13 patients had already achieved MMR (p = 0.54; Fisher's exact test; 2/15 patients were not analyzed at this time point). None of the 15 patients were switched from imatinib during these follow-up periods. No relationship was found between the patient groups defined by percentages of CD26 + SCs and risk stratification according to Hasford (n = 23, p > 0.05; Fisher's exact test), Sokal (n = 24, p > 0.05; Fisher's exact test), or EUTOS (n = 24, p > 0.05; Chi-square test) score. Also, no statistically significant difference was found between the frequency of either all
DISCUSSION
Recently, Herrmann et al. analyzed various surface antigens that were formerly hypothesized to define CML LSCs [17] . CD26 was reported to provide the highest specificity, which was confirmed by a series of thorough experiments including long-term culture-initiating cell (LTC-IC) and xenotransplantation assays. In the current study, we complemented these results by demonstrating the general applicability of this concept in CP CML patients. We also defined 3 patient groups based on different percentage of CD26 + cells in the stem cellenriched compartment.
Clear identification of the CD26 + and CD26 -SC populations was possible in each patient, even when one of the populations was almost missing. A quantitative analysis of CD26 + SCs enabled us to categorize prevented by adhering to the FMO control for CD38 when modifying or setting-up a new protocol. The position of CD38 -gate should not change for consistently processed and analyzed samples.
The proposed patient categorization raises the question if it reflects the actual clinical status or if it has a predictive value. We suggest that a larger LSC pool would produce larger quantities of clonal descendant cells. In line with this, we showed that WBC significantly differed among our 3 groups, with Group 1 patients having the highest WBC counts and the most CD26 + LSCs, which also corresponds with a previous report [10] . When looking at treatment response, we found a statistically significant difference among the 3 groups in achievement of MMR at month 12, but not month 18. Janssen et al. reported that patients without residual HSCs were less likely to achieve MMR at month 18 [15] . These results indicate a relationship between the initial number of LSCs and longer time to achieve an MMR. In regard to prognostic scores, Janssen et al. found that patients with residual HSCs showed significantly better EUTOS and EURO-scores [15] . In contrast, we found no such relationship for our 3 groups, and similarly no correlation was previously found when considering only the percentage of CD26 + SCs [17] . The CD26/DPPIV is a multifunctional protein expressed in many tissues and cell types. This limits the potential for LSC eradication through CD26 targeting [20] . However, inhibition of CD26 by vildagliptin reduced SCID repopulating activity of CML LSC cells [10] . Moreover, in two diabetic CML patients treated with nilotinib, BCR/ABL1 transcript level decreased after the start of gliptin therapy [10] . The potential of combined TKI and gliptin therapy for LSC eradication deserves further investigation, as gliptins are relatively safe and well characterized drugs, already widely used in treatment of diabetes.
In this study we confirmed that CD26 staining can accurately discriminate between LSCs and HSCs in all CML CP patients, which is of great clinical and diagnostic value. Additional studies are now required to determine whether the percentage of CD26 + SCs and the LSC/HSC proportion is of prognostic significance regarding survival and progression-free survival. In addition, further studies will be required to explore whether LSC phenotyping can be employed as a follow-up parameter in poorly responding or relapsing patients.
MATERIALS AND METHODS
Patients and sample collection
Bone marrow samples were collected from treatment-naïve, newly diagnosed CP CML patients. The patients' characteristics are shown in Table S1 . Written informed consent was provided by all patients. The study was approved by the local ethics committee of the Medical University of Vienna or ethics committee of University Hospital Brno, in accordance with the Declaration of Helsinki.
Immunophenotyping
Immunophenotyping and FACS-purification were performed on a FACSAria III instrument (BD Biosciences, USA) and FACSDiVa 6 software using the lyse wash method. Fresh or cryopreserved leukocytes were used. 
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-compartment) were observed for fresh versus thawed samples or with regard to the different sample processing methods used, when compared directly or upon overall comparison of differently processed/stained samples ( Figure S1 ).
Flow cytometry analysis
Flow cytometry analysis and quantification of CD26 + and CD26 -SCs were performed using FlowJo software (gating strategy shown in Figure S2 ). The position of the CD45 + 34 +
38
-SC gate was set according to FMO control for the CD38 antigen, i.e. a sample was stained with all other antibodies except CD38, thus revealing the fluorescence spread in this channel and the correct position for the CD38 -gate ( Figure S2 ). The proportion (%) of CD26 + and CD26 -SCs was 
-events acquired among the 3 patient groups (n = 31, p = 0.61; Kruskal-Wallis; ANOVA). 
FACS sorting
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+ cells (purified progenitor fraction). The gating strategy was patient dependent ( Figure S3 ). Due to the low yields of the broader CD26 + and CD26 -fractions, the purity of sorting was assessed on the purified progenitor fractions (identical sorting process) and reached a purity of 99.2 ± 0.7% [mean ± standard deviation (SD), n = 13]. FACS-purified subfractions containing limited cell numbers (described in Results) were analyzed by direct 
FISH analysis
FACS-purified cells were fixed by methanol-acetic acid solution (3:1; fixative solution). FISH analysis was performed on interphase nuclei to detect the BCR-ABL1 fusion using the XL BCR-ABL1 plus probe (MetaSystems, Germany). Whole volume of fixative solution (15-20 µl) with resuspended cells was spotted drop-wise onto a minimal slide area and let dry on a heater-plate at 56°C for 20 min. Hybridization with the FISH probe was performed according to the manufacturer recommendations with the following modifications: 7 µl of probe mixture was applied on slide; slides were washed in a 0.4X SSC/0.3% NP-40 solution (Abbott molecular, USA) at 73.5°C for 4 min; next slides were washed in 2X SSC/0.1% NP-40 solution (Abbott molecular, USA) at room temperature for 2 min. Fluorescence signals were evaluated using a Nikon Eclipse E80i fluorescence microscope and documented with LUCIA FISH software (Laboratory Imaging, Czech Republic).
RT-PCR analysis
FACS-purified subfractions containing limited cell numbers (as low as one cell) were analyzed for BCR-ABL1 positivity by direct nested reverse transcription PCR. Primers were used according to a previously published method [21] . Initially, cells were lysed using guanidine thiocyanate, followed by three quick freeze-thaw cycles at −80°C. The first-step of the nested RT-PCR was performed using the AffinityScript One-Step RT-PCR Kit (Agilent Technologies, USA) and included a singletube reverse transcription and the first PCR round [22] . The resulting PCR product was purified with a mixture of Exo I and FastAP Thermosensitive Alkaline Phosphatase at a ratio of 1:2 (Fermentas -Thermo Fisher Scientific, USA). The purified PCR product was diluted 100× in RNase-free water. For a second amplification, the HotStar Taq DNA Polymerase Kit (Qiagen, Germany) was used. Amplification products from both PCR rounds were visualized using a QX DNA Screening Kit on a QIAxcel Advanced instrument and analyzed using QIAxcel ScreenGel software (all Qiagen, Germany).
